Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616197 | 1.00 | SMYD3 (0.47) | SMYD3SYKNSD2SETD2JAK2 | |
| SCHEMBL3611297 | 1.00 | SMYD3 (0.47) | SMYD3SYKNSD2SETD2JAK2 | |
| SCHEMBL3610636 | 0.93 | SYK (0.51) | SMYD3SYKNSD2SETD2PBK | |
| SCHEMBL3610639 | 0.93 | SYK (0.51) | SMYD3SYKNSD2SETD2PBK | |
| SCHEMBL3618497 | 0.93 | SYK (0.51) | SMYD3SYKNSD2SETD2PBK | |
| SCHEMBL3611824 | 0.86 | SMYD3 (0.47) | SMYD3SYKNSD2SETD2PBK | |
| SCHEMBL3611827 | 0.86 | SMYD3 (0.47) | SMYD3SYKNSD2SETD2PBK | |
| SCHEMBL3606352 | 0.81 | SMYD3 (0.69) | SMYD3NSD2SETD2BRD4ATAD2 | |
| SCHEMBL3607953 | 0.81 | SMYD3 (0.69) | SMYD3NSD2SETD2BRD4ATAD2 | |
| SCHEMBL3606357 | 0.81 | SMYD3 (0.69) | SMYD3NSD2SETD2BRD4ATAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SMYD3 811/4885SYK 3494/4885NSD2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.